Drugs / BAT6005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05116709 | Nov 2021 → Jan 2024 | — | Bio-Thera Solutions | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAT6005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05116709 ↗ |
| Modality | Monoclonal antibody | “Anti-Tigitmab BAT6005 Injection” NCT05116709 ↗ |
| Target | TIGIT | “Anti-Tigitmab BAT6005 Injection” NCT05116709 ↗ |